Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Enanta Pharmaceuticals (ENTA) Operating Leases (2019 - 2025)

Enanta Pharmaceuticals' Operating Leases history spans 7 years, with the latest figure at $53.8 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 4.73% year-over-year to $53.8 million; the TTM value through Dec 2025 reached $53.8 million, down 4.73%, while the annual FY2025 figure was $54.8 million, 1.51% up from the prior year.
  • Operating Leases reached $53.8 million in Q4 2025 per ENTA's latest filing, down from $54.8 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $56.5 million in Q1 2025 to a low of $1.1 million in Q3 2021.
  • Average Operating Leases over 5 years is $30.6 million, with a median of $22.4 million recorded in 2022.
  • Peak YoY movement for Operating Leases: crashed 70.66% in 2021, then soared 1886.86% in 2022.
  • A 5-year view of Operating Leases shows it stood at $16.0 million in 2021, then surged by 36.98% to $21.9 million in 2022, then fell by 6.11% to $20.5 million in 2023, then surged by 175.06% to $56.5 million in 2024, then fell by 4.73% to $53.8 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's Operating Leases are $53.8 million (Q4 2025), $54.8 million (Q3 2025), and $55.7 million (Q2 2025).